ArticleFrontiers in pharmacology2026
Targeting the AcrAB-TolC efflux pump by small molecules selectively addressing the outer membrane factor TolC.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gram-negative bacteria express several efflux pump complexes extruding a broad spectrum of antibiotics. The major efflux pump in Methods: A virtual screening campaign was utilized to identify potential TolC binders. Virtual hits were investigated using a functional efflux assay, followed by synergy tests with piperacillin and determination of the intrinsic antibacterial potential. Bindings studies with individual efflux pump proteins were carried out. Synthetic chemistry was applied to improve the efficacy of the compound. Microbiological and biophysical tests were used to characterize the compounds with respect to synergistic activity with antibiotics and efflux pump binding. Results: We identified a small molecule interfering with efflux pump function, showing synergistic activity with piperacillin and binding to TolC which was further optimized at various positions. The most promising compounds revealed TolC-selective binding and shifted the minimum inhibitory concentration of piperacillin and levofloxacin at low micromolar concentrations. Conclusion: Our study provides evidence that TolC may represent a valid target for the development of an antibiotic adjuvant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.